Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19121664 | 1.00 | KDM4E (0.43) | KDM4EKCNH2SMN1; SMN2USP2DHFR | |
| SCHEMBL24974002 | 0.86 | KDM4E (0.41) | KDM4EKCNH2SMN1; SMN2USP2DHFR | |
| SCHEMBL18713943 | 0.86 | KDM4E (0.43) | KDM4ESMN1; SMN2USP2TSHRHTR2A | |
| SCHEMBL18713690 | 0.84 | KDM4E (0.44) | KDM4EKCNH2SMN1; SMN2USP2DHFR | |
| SCHEMBL21264332 | 0.81 | HRH4 (0.39) | KDM4EKCNH2TSHRHTR2AL3MBTL1 | |
| SCHEMBL765434 | 0.81 | GAA (0.43) | KDM4EKCNH2L3MBTL1 | |
| SCHEMBL31280268 | 0.81 | KDM4E (0.42) | KDM4EKCNH2HTR2A | |
| SCHEMBL31280738 | 0.81 | PDE2A (0.45) | KDM4EKCNH2TSHR | |
| SCHEMBL10175139 | 0.80 | HDAC4 (0.43) | SMN1; SMN2TSHRALDH1A1LMNATP53 | |
| SCHEMBL12606793 | 0.80 | CA12 (0.50) | HTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | KDM4E 4387/4885KCNH2 3399/4885SMN1; SMN2 2938/4885 |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | KDM4E 2815/4885KCNH2 1802/4885SMN1; SMN2 4361/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | KDM4E 2757/4885KCNH2 1115/4885SMN1; SMN2 2373/4885 |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | TNF, TNFRSF1A, TNFRSF9 | KDM4E 2815/4885KCNH2 1802/4885SMN1; SMN2 4361/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | KDM4E 4387/4885KCNH2 3399/4885SMN1; SMN2 2938/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KDM4E 2973/4885KCNH2 64/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.